Eltrombopag olamine for refractory immune-related thrombocytopenia induced by pembrolizumab in a non-small cell lung cancer patient

Lung Cancer. 2020 Aug:146:362-365. doi: 10.1016/j.lungcan.2020.05.015. Epub 2020 May 30.

Abstract

Objectives: Immune checkpoint inhibitors (ICIs) have shown antitumor activity against a wide variety of malignancies. ICI-induced immune-related thrombocytopenia is a rare immune-related adverse event (irAE). Little is known about the treatment of refractory immune-related thrombocytopenia in non-small cell lung cancer (NSCLC) patients treated with pembrolizumab.

Results: We report the case of a patient with advanced NSCLC complicated by pembrolizumab-induced refractory immune-related thrombocytopenia who showed remarkable improvement in the thrombocytopenia in response to eltrombopag olamine treatment.

Conclusion: Eltrombopag olamine can be a viable treatment option for refractory pembrolizumab-induced immune-related thrombocytopenia in an NSCLC patient.

Keywords: eltrombopag olamine; immune-related thrombocytopenia; non-small cell lung cancer; pembrolizumab; rituximab.

Publication types

  • Case Reports

MeSH terms

  • Antibodies, Monoclonal, Humanized
  • Benzoates
  • Carcinoma, Non-Small-Cell Lung* / complications
  • Carcinoma, Non-Small-Cell Lung* / drug therapy
  • Humans
  • Hydrazines
  • Lung Neoplasms* / complications
  • Lung Neoplasms* / drug therapy
  • Pyrazoles
  • Thrombocytopenia* / chemically induced
  • Thrombocytopenia* / drug therapy

Substances

  • Antibodies, Monoclonal, Humanized
  • Benzoates
  • Hydrazines
  • Pyrazoles
  • pembrolizumab
  • eltrombopag